21.37
3.59%
0.74
Pre-market:
21.38
0.010
+0.05%
Adma Biologics Inc stock is traded at $21.37, with a volume of 2.20M.
It is up +3.59% in the last 24 hours and up +35.42% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$20.63
Open:
$20.63
24h Volume:
2.20M
Relative Volume:
0.46
Market Cap:
$5.01B
Revenue:
$330.24M
Net Income/Loss:
$34.79M
P/E Ratio:
-106.85
EPS:
-0.2
Net Cash Flow:
$66.12M
1W Performance:
-0.47%
1M Performance:
+35.42%
6M Performance:
+127.10%
1Y Performance:
+430.27%
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ADMA | 21.37 | 5.01B | 330.24M | 34.79M | 66.12M | -0.20 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-23 | Resumed | Raymond James | Strong Buy |
Oct-13-22 | Initiated | Mizuho | Buy |
Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-04-19 | Initiated | Jefferies | Buy |
Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
Feb-07-19 | Resumed | H.C. Wainwright | Buy |
Dec-11-17 | Reiterated | Maxim Group | Buy |
Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
Jul-25-16 | Reiterated | Maxim Group | Buy |
May-13-15 | Reiterated | Maxim Group | Buy |
Dec-08-14 | Initiated | Oppenheimer | Outperform |
Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Biologics drops as auditor resigns - MSN
New Millennium Group LLC Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
First Turn Management LLC Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High? - Yahoo Finance
Oppenheimer & Co. Inc. Has $1.90 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
GSA Capital Partners LLP Sells 109,045 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Zacks Investment Research
Statutory Profit Doesn't Reflect How Good ADMA Biologics' (NASDAQ:ADMA) Earnings Are - Yahoo Finance
Entropy Technologies LP Purchases Shares of 37,850 ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
State of New Jersey Common Pension Fund D Has $2.27 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Janney Montgomery Scott LLC Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
29,143 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Aigen Investment Management LP - MarketBeat
ADMA Biologics, Inc. (NASDAQ:ADMA) Stake Raised by Amalgamated Bank - MarketBeat
Principal Financial Group Inc. Has $23.87 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Los Angeles Capital Management LLC Acquires 67,740 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Mesirow Financial Investment Management Inc. Sells 30,105 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Stock Traders Buy Large Volume of ADMA Biologics Call Options (NASDAQ:ADMA) - MarketBeat
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
Lisanti Capital Growth LLC Takes $4.70 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
HC Wainwright Predicts Increased Earnings for ADMA Biologics - MarketBeat
HC Wainwright Issues Positive Forecast for ADMA Biologics (NASDAQ:ADMA) Stock Price - MarketBeat
Earnings Beat: Here's What ADMA Biologics, Inc. (NASDAQ:ADMA) Analysts Are Forecasting For Next Year - Yahoo Finance
ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation - WICZ
Robeco Institutional Asset Management B.V. Purchases 68,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
New York State Teachers Retirement System Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Earnings call: ADMA Biologics reports robust growth, raises guidance - Investing.com India
ADMA Biologics stock soars to all-time high of $21.25 By Investing.com - Investing.com South Africa
ADMA Biologics (NASDAQ:ADMA) Stock Price Expected to Rise, Raymond James Analyst Says - MarketBeat
ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week HighWhat's Next? - MarketBeat
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
ADMA Biologics stock soars to all-time high of $21.25 - Investing.com
ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses - GlobeNewswire
Adma Biologics: Q3 Earnings Snapshot - CTPost
ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Reco - GuruFocus.com
ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge - Yahoo Finance
ADMA Biologics, Inc. Revises Earnings Guidance for the Fiscal Year 2024-2025 - Marketscreener.com
ADMA Biologics Reports Robust Q3 2024 Growth - TipRanks
ADMA Biologics Inc earnings beat by $0.02, revenue topped estimates - Investing.com
ADMA Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance UK
ADMA Biologics Inc Reports Q3 2024 Revenue of $119.8 Million, Su - GuruFocus.com
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Did ADMA Biologics (ADMA) Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Investigation - AccessWire
3 High Growth Tech Stocks Leading The US Market - Yahoo Finance
ADMA STOCK ALERT: Why is ADMA Biologics Under Investigation for Securities Fraud? Contact BFA Law if You Lost Money on Your Investment (Nasdaq:ADMA) - AccessWire
ADMA Biologics Inc (ADMA) Q3 2024: Everything You Need To Know A - GuruFocus.com
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):